Checkpoint Therapeutics is committed to advancing the development of cancer immunotherapy and targeted oncology treatments and creating accessible, effective and potentially more affordable options for patients everywhere.
Along with our leading candidates cosibelimab and olafertinib, we are dedicated to developing and bringing cancer therapies to market faster and actively pursuing product purchases, in-licensing and co-development opportunities that align with our areas of expertise, offering better patient outcomes and delivering significant value to the future of healthcare.